AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31859096 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy massage with lavender and chamomile oil
Number of subjects: 105
Study 31859096 — intervention group
Group type: COMPARATOR
Intervention: Placebo massage
Number of subjects: 105
Study 31859096 — intervention group
Group type: COMPARATOR
Intervention: Control group (daily routine care)
Number of subjects: 105
Study 30468803 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing the proportion of healthier foods available in worksite cafeterias
Number of subjects: 6
Study 28400146 — intervention group
Group type: EXPERIMENTAL
Intervention: PHQ-9 with alternate cutpoint of 6
Number of subjects: 153
Study 28400146 — intervention group
Group type: EXPERIMENTAL
Intervention: CES-D with traditional cutpoint of 16
Number of subjects: 153
Study 28400146 — intervention group
Group type: EXPERIMENTAL
Intervention: CES-D with stringent cutpoint of 22
Number of subjects: 153
Study 26189231 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose midazolam (MDZ) alone (G1)
Number of subjects: 60
Study 26189231 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose MDZ and dexmedetomidine (DEX) (G2)
Number of subjects: 60
Study 26189231 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose MDZ and DEX (G3)
Number of subjects: 60
Study 26189231 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose MDZ and high-dose DEX (G4)
Number of subjects: 60
Study 26189231 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose MDZ and low-dose DEX (G5)
Number of subjects: 60
Study 26189231 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose DEX alone (G6)
Number of subjects: 60
Study 23737255 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum containing Lactobacillus reuteri (2 × 10^8 CFU per dose), twice daily for 12 weeks
Number of subjects: 23
Study 23737255 — intervention group
Group type: COMPARATOR
Intervention: Placebo chewing gum
Number of subjects: 23
Study 20938783 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (100 mg)
Number of subjects: 12
Study 19225530 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (80 mg)
Number of subjects: 1613
Study 19225530 — intervention group
Group type: COMPARATOR
Intervention: Ramipril (5 or 10 mg)
Number of subjects: 1613
Study 17014994 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative local anaesthetic (2% lidocaine with 1:200,000 epinephrine)
Number of subjects: 142
Study 17014994 — intervention group
Group type: COMPARATOR
Intervention: Saline intraoral injection
Number of subjects: 142
Study 15259280 — intervention group
Group type: EXPERIMENTAL
Intervention: E2V/MPA triphasic
Number of subjects: 740
Study 15259280 — intervention group
Group type: COMPARATOR
Intervention: E2V/MPA biphasic
Number of subjects: 740
Study 15259280 — intervention group
Group type: COMPARATOR
Intervention: E2/NETA triphasic
Number of subjects: 740
Study 11411890 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention delivered by a computer aided learning package
Number of subjects: 95
Study 11411890 — intervention group
Group type: COMPARATOR
Intervention: Control group (read radiographs twice, received no intervention)
Number of subjects: 95
Study 11411890 — intervention group
Group type: COMPARATOR
Intervention: Second group (read radiographs once after the intervention)
Number of subjects: 95
Study 9431479 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma estradiol concentrations in premenopausal women with CHD
Number of subjects: 14
Study 9431479 — intervention group
Group type: EXPERIMENTAL
Intervention: Total estrogen concentrations in premenopausal women with CHD
Number of subjects: 14
Study 9431479 — intervention group
Group type: COMPARATOR
Intervention: Plasma estradiol concentrations in healthy control group
Number of subjects: 14
Study 9431479 — intervention group
Group type: COMPARATOR
Intervention: Total estrogen concentrations in healthy control group
Number of subjects: 14
Study 9431479 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone concentrations in premenopausal women with CHD
Number of subjects: 14
Study 9431479 — intervention group
Group type: COMPARATOR
Intervention: Progesterone concentrations in healthy control group
Number of subjects: 14
Study 7634748 — intervention group
Group type: EXPERIMENTAL
Intervention: Z-coefficient method
Number of subjects: 11
Study 7634748 — intervention group
Group type: COMPARATOR
Intervention: Cross-spectrum analysis
Number of subjects: 11
Study 2793610 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive identical tone bursts with infrequent shorter tones
Number of subjects: 0
Study 702245 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgical closure protocol
Number of subjects: 15
Study 702245 — intervention group
Group type: COMPARATOR
Intervention: Medical management protocol
Number of subjects: 15
Study 31272405 — intervention group
Group type: EXPERIMENTAL
Intervention: Median‐to‐ulnar nerve difference (MUD)
Number of subjects: 64
Study 31272405 — intervention group
Group type: EXPERIMENTAL
Intervention: Median‐to‐ulnar nerve ratio (MUR)
Number of subjects: 64
Study 31272405 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross‐sectional area of the median nerve at the pisiform level (CSA‐P)
Number of subjects: 64
Study 31272405 — intervention group
Group type: EXPERIMENTAL
Intervention: Swelling ratio (SR)
Number of subjects: 64
Study 31272405 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operator characteristic curve (ROC) for MUD
Number of subjects: 64
Study 31272405 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operator characteristic curve (ROC) for MUR
Number of subjects: 64
Study 31272405 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operator characteristic curve (ROC) for CSA‐P
Number of subjects: 64
Study 31272405 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operator characteristic curve (ROC) for SR
Number of subjects: 64
Study 27129584 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintered bovine bone substitute material (SBM, Alpha Bio's Graft®)
Number of subjects: 33
Study 27129584 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-sintered bovine bone substitute material (NSBM, Bio Oss®)
Number of subjects: 33
Study 26572698 — intervention group
Group type: EXPERIMENTAL
Intervention: Traffic noise exposure during 3 nights
Number of subjects: 10
Study 26572698 — intervention group
Group type: COMPARATOR
Intervention: No traffic noise during 3 nights
Number of subjects: 10
Study 25092108 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (LC) 1000 mg/d
Number of subjects: 47
Study 25092108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 21775070 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine (1,200 mg/m(2)/d Mondays through Friday) and Irinotecan (50 mg/m(2) weekly in four doses) with concurrent radiotherapy (50.4 Gy in 1.8‐Gy fractions) (Arm 1)
Number of subjects: 146
Study 21775070 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine (1,650 mg/m(2)/d Monday through Friday) and Oxaliplatin (50 mg/m(2) weekly in five doses) with concurrent radiotherapy (50.4 Gy in 1.8‐Gy fractions) (Arm 2)
Number of subjects: 146
Study 19383889 — intervention group
Group type: EXPERIMENTAL
Intervention: 12‐week Better Exercise Adherence after Treatment for Cancer intervention
Number of subjects: 41
Study 17616297 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban infusion followed by sirolimus-eluting stent (SES)
Number of subjects: 175
Study 17616297 — intervention group
Group type: COMPARATOR
Intervention: Abciximab plus bare-metal stent (BMS)
Number of subjects: 175
Study 15135267 — intervention group
Group type: EXPERIMENTAL
Intervention: 1mg of 17 beta‐estradiol orally combined with 100 mg progesterone
Number of subjects: 196
Study 15135267 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg transdermally combined with 100 mg progesterone
Number of subjects: 196
Study 15135267 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study 11295627 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary and lifestyle intervention (low-fat, soy-supplemented vegan diet, stress management, psychosocial support, exercise programs)
Number of subjects: 93
Study 11295627 — intervention group
Group type: COMPARATOR
Intervention: Control group (watchful waiting)
Number of subjects: 93
Study 11295627 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary and lifestyle intervention
Number of subjects: 93
Study 9133340 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-coated tablet formulation (Femavit 1.25)
Number of subjects: 18
Study 9133340 — intervention group
Group type: COMPARATOR
Intervention: Oral suspension
Number of subjects: 18
Study 9133340 — intervention group
Group type: EXPERIMENTAL
Intervention: Both preparations
Number of subjects: 18
Study 8188994 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrolyte (240 mosm/l)
Number of subjects: 45
Study 8188994 — intervention group
Group type: COMPARATOR
Intervention: Glucolyte (340 mOsm/l)
Number of subjects: 45
Study 3532900 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserine (80 mg/day for 6 months)
Number of subjects: 27
Study 3532900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 3532900 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserine
Number of subjects: 27
Study 29994756 — intervention group
Group type: EXPERIMENTAL
Intervention: Stochastic training of neural networks via successive convex approximations
Number of subjects: 0
Study 26681725 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal glucagon (3 mg)
Number of subjects: 75
Study 26681725 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular glucagon (1 mg)
Number of subjects: 75
Study 25296655 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary Multistep Medication Review (3MR)
Number of subjects: 600
Study 25296655 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 600
Study 21864869 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity resistance exercise (RE)
Number of subjects: 12
Study 21864869 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 12
Study 19841860 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZOL) 5 mg infusion
Number of subjects: 9
Study 19841860 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 9
Study 17650792 — intervention group
Group type: EXPERIMENTAL
Intervention: Biliary drainage via endoscope (ENBD) combined with Chinese drug medication (CTG)
Number of subjects: 16
Study 17650792 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment with ENBD alone (RTG)
Number of subjects: 16
Study 17650792 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) with simple gallbladder stone
Number of subjects: 16
Study 15618250 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg twice daily for 3 months)
Number of subjects: 30
Study 15618250 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg for 3 months)
Number of subjects: 30
Study 11895821 — intervention group
Group type: EXPERIMENTAL
Intervention: Provision of 10 pairs of Informed Choice leaflets and a training session in their use
Number of subjects: 886
Study 10465169 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone 30 mg once daily for 14 days
Number of subjects: 56
Study 10465169 — intervention group
Group type: COMPARATOR
Intervention: Identical placebo
Number of subjects: 56
Study 8588170 — intervention group
Group type: EXPERIMENTAL
Intervention: Lift testing before and after a therapeutic trial
Number of subjects: 55
Study 8588170 — intervention group
Group type: COMPARATOR
Intervention: Lift testing only at the conclusion of the therapeutic trial
Number of subjects: 55
Study 8597617 — intervention group
Group type: EXPERIMENTAL
Intervention: e-PTFE (Gore-Tex GTAM) membrane applied to one fenestration
Number of subjects: 7
Study 8597617 — intervention group
Group type: COMPARATOR
Intervention: Control group (no membrane applied)
Number of subjects: 7
Study 7017485 — intervention group
Group type: EXPERIMENTAL
Intervention: guacetisal
Number of subjects: 30
Study 7017485 — intervention group
Group type: COMPARATOR
Intervention: oxolamine phosphate
Number of subjects: 30
Study 31083704 — intervention group
Group type: EXPERIMENTAL
Intervention: AW group (18% oral carbohydrate solution)
Number of subjects: 34
Study 31083704 — intervention group
Group type: COMPARATOR
Intervention: PW group (plain water)
Number of subjects: 34
Study 31083704 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study 28012183 — intervention group
Group type: EXPERIMENTAL
Intervention: Eczema Area and Severity Index (EASI)
Number of subjects: 25
Study 28012183 — intervention group
Group type: EXPERIMENTAL
Intervention: objective Scoring Atopic Dermatitis (oSCORAD)
Number of subjects: 25
Study 28012183 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigator's Global Assessment (IGA)
Number of subjects: 25
Study 28012183 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel greyscale
Number of subjects: 25
Study 28012183 — intervention group
Group type: EXPERIMENTAL
Intervention: All scoring measures
Number of subjects: 25
Study 28012183 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythema component analysis
Number of subjects: 25
Study 25873139 — intervention group
Group type: EXPERIMENTAL
Intervention: Grocery store-based dietary counselling
Number of subjects: 55
Study 25873139 — intervention group
Group type: COMPARATOR
Intervention: Clinic-based dietary counselling
Number of subjects: 55
Study 25873139 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 55
Study 23528626 — intervention group
Group type: EXPERIMENTAL
Intervention: mesalamine (Asacol 800‐mg tablet) 4.8 g/day
Number of subjects: 281
Study 23528626 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 281
Study 23528626 — intervention group
Group type: EXPERIMENTAL
Intervention: mesalamine (Asacol 800‐mg tablet) 4.8 g/day after excluding ineligible patients
Number of subjects: 281
Study 23528626 — intervention group
Group type: COMPARATOR
Intervention: placebo after excluding ineligible patients
Number of subjects: 281
Study 21059830 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP ≥140 mmHg at baseline
Number of subjects: 1791
Study 21059830 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP ≥140 mmHg On-Study
Number of subjects: 1791
Study 21059830 — intervention group
Group type: EXPERIMENTAL
Intervention: DBP <70 mmHg at baseline
Number of subjects: 1791
Study 21059830 — intervention group
Group type: EXPERIMENTAL
Intervention: DBP <70 mmHg On-Study
Number of subjects: 1791
Study 21059830 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP ≥140 with DBP <70 mmHg at baseline
Number of subjects: 1791
Study 21059830 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP ≥140 with DBP <70 mmHg On-Study
Number of subjects: 1791
Study 19344437 — intervention group
Group type: EXPERIMENTAL
Intervention: Valganciclovir (900 mg/day)
Number of subjects: 76
Study 19344437 — intervention group
Group type: COMPARATOR
Intervention: Oral ganciclovir (3000 mg/day)
Number of subjects: 76
Study 17708626 — intervention group
Group type: EXPERIMENTAL
Intervention: Taiji and Qigong (TQ)
Number of subjects: 50
Study 17708626 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (CON)
Number of subjects: 50
Study 15008318 — intervention group
Group type: EXPERIMENTAL
Intervention: Active warming with a carbon-fiber heating blanket set to 42 degrees C
Number of subjects: 30
Study 15008318 — intervention group
Group type: COMPARATOR
Intervention: Passive warming with a carbon-fiber heating blanket switched off
Number of subjects: 30
Study 11683187 — intervention group
Group type: EXPERIMENTAL
Intervention: Incubator cover
Number of subjects: 9
Study 11683187 — intervention group
Group type: COMPARATOR
Intervention: No incubator cover
Number of subjects: 9
Study 9743397 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihistamines (1 mg/kg diphenhydramine and 4 mg/kg cimetidine)
Number of subjects: 40
Study 9743397 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 8048862 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sphincterotomy (ES)
Number of subjects: 186
Study 8048862 — intervention group
Group type: COMPARATOR
Intervention: Control group (cholecystolithiasis only)
Number of subjects: 186
Study 2563688 — intervention group
Group type: EXPERIMENTAL
Intervention: Benorylate 4 g
Number of subjects: 0
Study 2563688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30696465 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended-learning training (e-learning + skills-training workshop)
Number of subjects: 480
Study 30696465 — intervention group
Group type: COMPARATOR
Intervention: Information leaflet about reputable websites
Number of subjects: 480
Study 28166784 — intervention group
Group type: EXPERIMENTAL
Intervention: CCM-based intervention with APC-CHW team including a minimum of three clinic visits, three home visits, and Chronic Disease Self-Management Program group workshops
Number of subjects: 516
Study 28166784 — intervention group
Group type: EXPERIMENTAL
Intervention: CCM-based intervention with APC-CHW team
Number of subjects: 516
Study 25733462 — intervention group
Group type: COMPARATOR
Intervention: High-protein preload (PRO; 29 g)
Number of subjects: 20
Study 25733462 — intervention group
Group type: COMPARATOR
Intervention: High-calcium preload (CAL; 1170 mg)
Number of subjects: 20
Study 25733462 — intervention group
Group type: COMPARATOR
Intervention: High-protein and high-calcium preload (PROCAL)
Number of subjects: 20
Study 25733462 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calcium and low-protein control preload (CON)
Number of subjects: 20
Study 25733462 — intervention group
Group type: COMPARATOR
Intervention: High-protein preload (PRO)
Number of subjects: 20
Study 25733462 — intervention group
Group type: COMPARATOR
Intervention: High-calcium preload (CAL)
Number of subjects: 20
Study 23203707 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservative-free latanoprost (T2345)
Number of subjects: 0
Study 23203707 — intervention group
Group type: COMPARATOR
Intervention: BAK-preserved latanoprost (BPL)
Number of subjects: 0
Study 21386896 — intervention group
Group type: EXPERIMENTAL
Intervention: Salient distractor (high contrast)
Number of subjects: 0
Study 21386896 — intervention group
Group type: EXPERIMENTAL
Intervention: Target (low contrast)
Number of subjects: 0
Study 18191090 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue light-filter intraocular lenses (yellow IOL group)
Number of subjects: 60
Study 18191090 — intervention group
Group type: COMPARATOR
Intervention: Ultraviolet-filter intraocular lenses (clear IOL group)
Number of subjects: 60
Study 18191090 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IOL groups
Number of subjects: 60
Study 16780997 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alfa‐2b (1.5 microg/kg/week)
Number of subjects: 36
Study 16780997 — intervention group
Group type: COMPARATOR
Intervention: peginterferon alfa‐2a (180 microg/week)
Number of subjects: 36
Study 14644515 — intervention group
Group type: EXPERIMENTAL
Intervention: Central arm (rapid diagnostic system)
Number of subjects: 88
Study 14644515 — intervention group
Group type: COMPARATOR
Intervention: Conventional arm (local investigation)
Number of subjects: 88
Study 11025704 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy for benign prostatic hyperplasia
Number of subjects: 0
Study 8775354 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity training (50% of VO2max)
Number of subjects: 197
Study 8775354 — intervention group
Group type: COMPARATOR
Intervention: High intensity training (85% of VO2max)
Number of subjects: 197
Study 1457115 — intervention group
Group type: EXPERIMENTAL
Intervention: ORG 9426 at 570 micrograms/kg
Number of subjects: 36
Study 1457115 — intervention group
Group type: EXPERIMENTAL
Intervention: ORG 9426 at 710 micrograms/kg
Number of subjects: 36
Study 1457115 — intervention group
Group type: EXPERIMENTAL
Intervention: ORG 9426 at 850 micrograms/kg
Number of subjects: 36
Study 1457115 — intervention group
Group type: EXPERIMENTAL
Intervention: ORG 9426 (all doses)
Number of subjects: 36
Study 6233348 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (n = 24)
Number of subjects: 87
Study 6233348 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy (n = 24)
Number of subjects: 87
Study 6233348 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy plus pharmacotherapy (n = 22)
Number of subjects: 87
Study 6233348 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy plus active placebo (n = 17)
Number of subjects: 87
Study 6233348 — intervention group
Group type: COMPARATOR
Intervention: Single treatment modalities
Number of subjects: 87
Study 30654370 — intervention group
Group type: EXPERIMENTAL
Intervention: Iso osmolar medium (IOCM)
Number of subjects: 146
Study 30654370 — intervention group
Group type: COMPARATOR
Intervention: High osmolality contrast medium (HOCM)
Number of subjects: 146
Study 29424680 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention with personalized normative feedback screen
Number of subjects: 1057
Study 29424680 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 1057
Study 26825365 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopacin(®) 75 mg
Number of subjects: 48
Study 26825365 — intervention group
Group type: COMPARATOR
Intervention: Reference drug (originator)
Number of subjects: 48
Study 24952740 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice network-based care management intervention (three home visits, 24 structured telephone monitoring contacts, self-monitoring of blood glucose levels after T1 in 3-month intervals)
Number of subjects: 582
Study 24952740 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice network-based care management intervention
Number of subjects: 582
Study 24952740 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 582
Study 23054063 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 1,000 mg + Caffeine 130 mg (PCF)
Number of subjects: 0
Study 23054063 — intervention group
Group type: COMPARATOR
Intervention: Sumatriptan 50 mg (SUM)
Number of subjects: 0
Study 20735782 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic comprising Bifidobacterium longum and Synergy 1
Number of subjects: 35
Study 20735782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 18370567 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 0